Business Context and Reporting Period
Company: GSK plc
Filing Type: Form 6-K (Report of Foreign Private Issuer)
Date Issued: January 5, 2026
Subject: Regulatory approval of Nucala (mepolizumab) in China for the treatment of Chronic Obstructive Pulmonary Disease (COPD).
Key Financial Metrics
This filing is a regulatory announcement regarding a specific product approval and does not contain financial statements. Consequently, the filing text does not provide clear values for revenue, profit, cash flow, margins, debt, or liquidity metrics.
Material Changes and Developments
- Regulatory Milestone: China's National Medical Products Administration (NMPA) approved Nucala as an add-on maintenance treatment for adults with inadequately controlled COPD characterized by raised blood eosinophils.
- Market Position: Nucala is the first and only monthly biologic approved in China studied in a wide COPD population with blood eosinophil counts (BEC) starting as low as 150 cells/µL.
- Target Population: Approximately 100 million people in China have COPD. Among patients inadequately controlled on inhaled triple therapy, 67% have a BEC above 150 cells/µL.
- Clinical Evidence: Approval was based on positive Phase III trials (MATINEE and METREX) showing statistically significant reductions in moderate/severe exacerbations compared to placebo.
Guidance, Outlook, and Management Commentary
Management Commentary: Kaivan Khavandi, SVP & Global Head of Respiratory, Immunology & Inflammation R&D, highlighted the high incidence and mortality of COPD in China. He stated that Nucala offers a monthly add-on maintenance treatment to reduce exacerbations, including those leading to emergency department visits and hospitalizations, which account for a large proportion of annual direct medical costs.
Global Outlook: Nucala is already approved in China for severe eosinophilic asthma, chronic rhinosinusitis with nasal polyps, and eosinophilic granulomatosis with polyangiitis. It is approved for COPD in the US. Regulatory submissions are under review globally, including a recent positive CHMP opinion in Europe for COPD.
Risks: The filing includes a standard cautionary statement that forward-looking statements are subject to risks and uncertainties, including those described in GSK's 2024 Form 20-F and Q3 2025 results.
Investor Verification Checklist
- Verify the commercial launch timeline and pricing strategy for Nucala in the Chinese COPD market.
- Review the specific reimbursement status of Nucala for COPD within China's national and provincial insurance schemes.
- Assess the competitive landscape for biologics in the Chinese respiratory market post-approval.
- Monitor upcoming regulatory decisions in Europe and other key markets for COPD indications.
- Review GSK's full 2025 financial results to understand the broader financial context of this product launch.